<DOC>
	<DOCNO>NCT02070705</DOCNO>
	<brief_summary>This clinical trial study image technique know dynamic contrast enhance magnetic resonance imaging ( DCE MRI ) identify presence pancreatic cancer . DCE MRI procedure take detailed picture functional structural property inside body use magnetic field radio frequency pulse . These picture may help identify underlying malignancy patient high risk active malignancy patient undergone chemotherapy pancreatic cancer .</brief_summary>
	<brief_title>DCE MRI Diagnosing Patients With Pancreatic Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I. Assess ability DCE MRI identify presence pancreatic cancer patient high risk hereditary pancreatic cancer . II . Assess ability DCE MRI identify presence pancreatic cancer patient cystic lesion pancreas . III . Assess ability DCE MRI accurately predict tumor margin patient undergone chemotherapy pancreatic cancer . SECONDARY OBJECTIVES : I . In three group list clinical factor associate presence pancreatic cancer analyze ; addition , disease free survival overall survival analyze group . OUTLINE : Patients assign 1 3 group . ARM I ( High-risk familial hereditary pancreatic cancer ) : Patients undergo DCE MRI 3 scan . ARM II ( Intraductal Papillary Mucinous Neoplasms ( IPMN ) ) : Patients undergo DCE MRI prior surgery . ARM III ( Unresectable pancreatic cancer ) : Patients undergo DCE MRI neoadjuvant therapy .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<criteria>Must consent Oregon Pancreatic Tumor Registry ( OPTR ) Must contraindication MRI intravenous ( IV ) contrast administration Allergy intravenous contrast agent Prohance Ferumoxytol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>